BRM.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

Stats
Dagens volum	6 585.00
Gjennomsnittsvolum	2 534.00
Markedsverdi	88.44B
EPS	€0 ( 2024-04-25 )
Neste inntjeningsdato	( €0 ) 2024-07-26
Last Dividend	€0.570 ( 2023-07-06 )
Next Dividend	€0 ( N/A )
P/E	12.10
ATR14	€0.0880 (0.21%)

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: -0.46 (neutral)

Signal:(65.485) Neutral

Bristol-Myers Squibb Co Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Bristol-Myers Squibb Co Korrelasjon - Valuta/Råvare

0.50
( weak )

0.70
( moderate )

0.57
( weak )

0.71
( moderate )

-0.74
( moderate negative )

-0.78
( moderate negative )

Bristol-Myers Squibb Co Økonomi

Annual	2023
Omsetning:	€45.01B
Bruttogevinst:	€34.31B (76.24 %)
EPS:	€3.88

FY	2023
Omsetning:	€45.01B
Bruttogevinst:	€34.31B (76.24 %)
EPS:	€3.88

FY	2022
Omsetning:	€46.16B
Bruttogevinst:	€36.02B (78.04 %)
EPS:	€2.97

FY	2021
Omsetning:	€46.39B
Bruttogevinst:	€36.45B (78.57 %)
EPS:	€3.15

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0.540 (N/A)	€0.570 (N/A)	€0.570 (N/A)	€0.570 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.68 - Stable (13.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.215	1999-06-30
Last Dividend	€0.570	2023-07-06
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	97	--
Total Paid Out	€33.94	--
Avg. Dividend % Per Year	0.00%	--
Score	4.93	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.68
Div. Directional Score	8.19	--

Next Divdend (Est)
(2024-05-08)

€0.580 Estimate 21.49 %

Dividend Stability

0.57 Average

Dividend Score

4.93

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
PSM.DE	Ex Dividend Junior	2023-07-03	Annually	0.00%
BOSS.DE	Ex Dividend Knight	2023-05-10	Annually	0.00%
INH.DE	Ex Dividend Knight	2023-05-18	Annually	0.00%
SRB.DE	Ex Dividend Knight	2023-11-09	Quarterly	0.00%
DAM.DE	Ex Dividend Junior	2023-05-10	Annually	0.00%
LOM.DE	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
47T.F	Ex Dividend Knight	2023-09-06	Annually	0.00%
UZU.DE	Ex Dividend Knight	2023-05-17	Annually	0.00%
ENL.DE	Ex Dividend Knight	2023-07-24	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.178	1.500	6.43	9.65	[0 - 0.5]
returnOnAssetsTTM	0.0843	1.200	7.19	8.63	[0 - 0.3]
returnOnEquityTTM	0.263	1.500	8.19	10.00	[0.1 - 1]
payoutRatioTTM	0.591	-1.000	4.09	-4.09	[0 - 1]
currentRatioTTM	1.427	0.800	7.86	6.29	[1 - 3]
quickRatioTTM	1.237	0.800	7.43	5.94	[0.8 - 2.5]
cashRatioTTM	0.515	1.500	8.25	10.00	[0.2 - 2]
debtRatioTTM	0.436	-1.500	2.74	-4.11	[0 - 0.6]
interestCoverageTTM	8.08	1.000	8.12	8.12	[3 - 30]
operatingCashFlowPerShareTTM	6.82	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.23	2.00	6.89	10.00	[0 - 20]
debtEquityRatioTTM	1.409	-1.500	4.36	-6.55	[0 - 2.5]
grossProfitMarginTTM	0.762	1.000	0.627	0.627	[0.2 - 0.8]
operatingProfitMarginTTM	0.209	1.000	7.82	7.82	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.334	1.000	9.25	9.25	[0.2 - 2]
assetTurnoverTTM	0.473	0.800	-0.180	-0.144	[0.5 - 2]
Total Score				10.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.47	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.263	2.50	8.84	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.23	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.258	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.82	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	0.591	1.500	4.09	-4.09	[0 - 1]
pegRatioTTM	0.194	1.500	-2.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.308	1.000	4.80	0	[0.1 - 0.5]
Total Score				5.68

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.